Cochrane · systematic review · CD000957
Methotrexate for treating rheumatoid arthritis
Lopez‐Olivo, MA, Siddhanamatha, HR, Shea, B, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 5 · 71.4%High 1 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Methotrexate for rheumatoid arthritis
Population: patients with rheumatoid arthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
ACR 50 American College of Rheumatology improvement criteria | RR 3 [1.5, 6] | 1 study · 300 participants | Moderate Downgraded: imprecision, publication bias |
Remission3 | no estimate extracted | 1 study · 189 participants | Low Downgraded: imprecision, publication bias |
Functional Status Health Assessment Questionnaire Disability Index . Scale from: 0 to 3 | no estimate extracted | 2 studies · 298 participants | Moderate Downgraded: risk of bias, imprecision, publication bias |
Health‐Related Quality of Life at least 20% improvement | RR 1.5 [1, 2.1] | 1 study · 263 participants | Moderate Downgraded: imprecision, publication bias |
Radiographic Progression Increase in erosion scores of > 3 units | RR 0.31 [0.11, 0.86] | 1 study · 219 participants | Moderate Downgraded: imprecision, publication bias |
Discontinuations due to adverse events | RR 2.1 [1.3, 3.3] | 6 studies · 613 participants | High |
Serious Adverse Events | RR 1.4 [0.36, 5.7] | 2 studies · 330 participants | Moderate Downgraded: risk of bias, imprecision, publication bias |